Cultrex UltiMatrix RGF BME is an extracellular-matrix hydrogel to be used during the culturing of organoids and pluripotent stem cells. The product addresses the need for a dependable, high-concentration cell-scaffolding matrix with compositional and physical properties specifically designed for use in generating 2D and 3D cell culture models, the firm said.

Improvements to Cultrex UltiMatrix RGF BME include increased total protein content, optimized extracellular matrix protein composition, high levels of entactin, and improved tensile strength. These characteristics reduce the dependency on supplemental growth factors during cell culture. The reagent can be used for drug discovery research, personalized medicines, and regenerative medicine applications.

The new product is offered through R&D Systems, a Bio-Techne company.

Luminary licenses TcBuster CAR T tech from Bio-Techne
Luminary Therapeutics has signed a license agreement with Bio-Techne for the use of its TcBuster chimeric antigen receptor (CAR) T technology for the...

Bio-Techne invests in China-based cell and gene therapy media company
Bio-Techne has made an initial minority strategic equity investment in Changzhou Eminence Biotechnology. The companies will synergistically work on the...

ScaleReady launches to improve T-cell manufacturing
A new joint venture called ScaleReady has been launched to develop tools and technologies for use in cell and gene therapy manufacturing. The firm is...

Bio-Techne opens GMP manufacturing facility
Bio-Techne has opened a 61,000-sq-ft good manufacturing practice (GMP) manufacturing facility in St. Paul, MN. The space will be dedicated to large-scale...

Bio-Techne rebrands genome engineering as part of R&D Systems portfolio
Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.